---
title: "New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284279440.md"
description: "MediciNova, Inc. announced a significant discovery in brain metastasis from a study by the Spanish National Cancer Research Centre. The research highlights the role of macrophage migration inhibitory factor (MIF) in reprogramming CD74-positive microglia and macrophages. The study, published in \"Cancer Research,\" demonstrates the effectiveness of ibudilast in modulating this pathway. MediciNova is listed on NASDAQ (MNOV) and Tokyo Stock Exchange (4875)."
datetime: "2026-04-27T23:01:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284279440.md)
  - [en](https://longbridge.com/en/news/284279440.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284279440.md)
---

# New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

In La Jolla, California, on April 27, 2026, MediciNova, Inc. revealed that a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) pinpointed a significant discovery in brain metastasis. The researchers identified that macrophage migration inhibitory factor (MIF) plays a crucial role in reprogramming CD74-positive microglia and macrophages. This vulnerability was detailed in a recent publication in the reputable journal "Cancer Research" from March 2026. The study showcased the effectiveness of ibudilast, a brain-penetrant small molecule, in modulating this pathway. MediciNova, Inc. is a biopharmaceutical company listed on the NASDAQ Global Market under the ticker symbol MNOV and the Tokyo Stock Exchange under Code Number 4875.

### Related Stocks

- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)
- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)

## Related News & Research

- [Purple Biotech presents new preclinical IM1240 cancer data at EACR 2026 congress](https://longbridge.com/en/news/295224384.md)
- [GRAL: Significant growth, clinical validation, and regulatory milestones position the test for broader adoption](https://longbridge.com/en/news/295557836.md)
- [BioSapien targets mid-2026 start for Phase I cancer implant trial in Abu Dhabi](https://longbridge.com/en/news/295365376.md)
- [Tuhura Biosciences releases corporate deck outlining strategy to tackle cancer immunotherapy resistance](https://longbridge.com/en/news/295567242.md)
- [Erasca appoints Charles Fuchs as president of R&D](https://longbridge.com/en/news/295404808.md)